Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Essential role and therapeutic targeting of the glomerular endothelial glycocalyx in lupus nephritis
Hiroyuki Kadoya, … , Chaim O. Jacob, János Peti-Peterdi
Hiroyuki Kadoya, … , Chaim O. Jacob, János Peti-Peterdi
Published September 1, 2020
Citation Information: JCI Insight. 2020;5(19):e131252. https://doi.org/10.1172/jci.insight.131252.
View: Text | PDF
Research Article Nephrology

Essential role and therapeutic targeting of the glomerular endothelial glycocalyx in lupus nephritis

  • Text
  • PDF
Abstract

Lupus nephritis (LN) is a major organ complication and cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). There is an unmet medical need for developing more efficient and specific, mechanism-based therapies, which depends on improved understanding of the underlying LN pathogenesis. Here we present direct visual evidence from high-power intravital imaging of the local kidney tissue microenvironment in mouse models showing that activated memory T cells originated in immune organs and the LN-specific robust accumulation of the glomerular endothelial glycocalyx played central roles in LN development. The glomerular homing of T cells was mediated via the direct binding of their CD44 to the hyaluronic acid (HA) component of the endothelial glycocalyx, and glycocalyx-degrading enzymes efficiently disrupted homing. Short-course treatment with either hyaluronidase or heparinase III provided long-term organ protection as evidenced by vastly improved albuminuria and survival rate. This glycocalyx/HA/memory T cell interaction is present in multiple SLE-affected organs and may be therapeutically targeted for SLE complications, including LN.

Authors

Hiroyuki Kadoya, Ning Yu, Ina Maria Schiessl, Anne Riquier-Brison, Georgina Gyarmati, Dorinne Desposito, Kengo Kidokoro, Matthew J. Butler, Chaim O. Jacob, János Peti-Peterdi

×

Figure 2

Enumeration and characterization of leukocytes infiltrating the kidneys of 6- to 7-month-old female NZM.2328 WT mice.

Options: View larger image (or click on image) Download as PowerPoint
Enumeration and characterization of leukocytes infiltrating the kidneys ...
(A) Representative flow cytometry plots of infiltrating leukocyte subsets in the glomerular (glom) and tubulointerstitial (Tub-int) kidney compartments. (B) Flow cytometry–based quantification of the indicated leukocyte subsets infiltrating the glom (white symbols) and the Tub-int (green symbols) compartments. Each symbol represents an individual mouse. (C) Comparison of CD4+, CD8+, and CD4–CD8– T cells (double-negative T cells, DNT) presented as percentage of CD3+ cells in kidney compartments and spleens. Data are presented as box plots as in Figure 1. (D) Representative flow cytometry contour plots and quantification of activated memory T cells (presented as % of CD3+) in kidney compartments and spleens. (E) Representative contour plots and quantification of % CD69+ cells on activated memory T cells in kidney compartments and spleens. (B–E) Each symbol represents an individual mouse. Only statistically significant differences are marked, based on using 1-way ANOVA followed by Tukey’s multiple-comparisons test (C–E). *P < 0.01, **P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts